![Even stronger obesity drug could further upend weight-loss care](https://assets1.cbsnewsstatic.com/hub/i/r/2023/04/27/c6e37647-872a-4465-923f-d33eb5033663/thumbnail/1200x630/df1df8fcdc01e7e8d3ff0bfcec732921/gettyimages-1245721969.jpg)
Even stronger obesity drug could further upend weight-loss care
CBSN
As a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
Tirzepatide, an Eli Lilly and Co. drug approved to treat Type 2 diabetes under the brand name Mounjaro, helped people with the disease who were overweight or had obesity lose up to 16% of their body weight, or more than 34 pounds, over nearly 17 months, the company said on Thursday.
The late-stage study of the drug for weight loss adds to earlier evidence that similar participants without diabetes lost up to 22% of their body weight over that period with weekly injections of the drug. For a typical patient on the highest dose, that meant shedding more than 50 pounds.
![](/newspic/picid-6252001-20250216030556.jpg)
This story previously aired on Feb. 10, 2024. It was updated on Feb. 15, 2025. AMIE HARWICK (video): You can seek therapy to address an issue like depression, anxiety, a breakup. You can also seek therapy to be a better you! GARETH PURSEHOUSE (voicemail): I have so much I need to say. Please give me a chance to just say it. … Please (crying) please.
![](/newspic/picid-6252001-20250216003423.jpg)
Signaling a major shift in civil rights enforcement, the federal agency that enforces workplace anti-discrimination laws has moved to dismiss six of its own cases on behalf of workers alleging gender identity discrimination, arguing that the cases now conflict with President Donald Trump's recent executive order, court documents say.